Literature DB >> 10571941

CTNS mutations in patients with cystinosis.

Y Anikster1, V Shotelersuk, W A Gahl.   

Abstract

Cystinosis is an autosomal recessive lysosomal storage disease caused by mutations in the gene CTNS. The CTNS gene product, cystinosin, has 367 amino acids and seven transmembrane domains and is thought to transport cystine out of lysosomes. The most common form of cystinosis, the nephropathic or infantile type, is characterized by renal failure at 10 years of age and other systemic complications. To date, 32 different CTNS mutations have been described in nephropathic cystinosis patients. Intermediate cystinosis, with later onset of renal disease, has been associated with three different CTNS mutations. Benign or nonnephropathic cystinosis, with symptoms related only to corneal crystals and photophobia, has been associated with two other CTNS mutations. In general, only certain splicing or missense mutations are associated with milder cystinosis phenotypes. Hum Mutat 14:454-458, 1999. Published 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571941     DOI: 10.1002/(SICI)1098-1004(199912)14:6<454::AID-HUMU2>3.0.CO;2-H

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  25 in total

1.  End-stage renal failure as manifestation of adolescent cystinosis.

Authors:  Michaela Marx; Christian Plank; Bettina Zimmermann; Maike Graupner; Michael Kiehntopf; Jörg Dötsch
Journal:  Eur J Pediatr       Date:  2004-02-07       Impact factor: 3.183

2.  Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.

Authors:  Jennifer L Simpson; Chyong Jy Nien; Kevin J Flynn; James V Jester
Journal:  Mol Vis       Date:  2011-10-08       Impact factor: 2.367

3.  Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin.

Authors:  Gundula Min-Oo; Anny Fortin; Jean-François Poulin; Philippe Gros
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

4.  Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter.

Authors:  V Kalatzis; S Cherqui; C Antignac; B Gasnier
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

5.  Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.

Authors:  Gundula Min-Oo; Kodjo Ayi; Silayuv E Bongfen; Mifong Tam; Irena Radovanovic; Susan Gauthier; Helton Santiago; Antonio Gigliotti Rothfuchs; Ester Roffê; Alan Sher; Alaka Mullick; Anny Fortin; Mary M Stevenson; Kevin C Kain; Philippe Gros
Journal:  Exp Parasitol       Date:  2010-02-26       Impact factor: 2.011

6.  Insights into novel cellular injury mechanisms by gene expression profiling in nephropathic cystinosis.

Authors:  Poonam Sansanwal; Li Li; Szu-Chuan Hsieh; Minnie M Sarwal
Journal:  J Inherit Metab Dis       Date:  2010-09-24       Impact factor: 4.982

Review 7.  Potential use of stem cells as a therapy for cystinosis.

Authors:  Celine J Rocca; Stephanie Cherqui
Journal:  Pediatr Nephrol       Date:  2018-05-22       Impact factor: 3.714

8.  The promoter of a lysosomal membrane transporter gene, CTNS, binds Sp-1, shares sequences with the promoter of an adjacent gene, CARKL, and causes cystinosis if mutated in a critical region.

Authors:  C Phornphutkul; Y Anikster; M Huizing; P Braun; C Brodie; J Y Chou; W A Gahl
Journal:  Am J Hum Genet       Date:  2001-08-14       Impact factor: 11.025

9.  Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis.

Authors:  Poonam Sansanwal; Benedict Yen; William A Gahl; Yewei Ma; Lihua Ying; Lee-Jun C Wong; Minnie M Sarwal
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

10.  Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping.

Authors:  Aude Servais; Vincent Morinière; Jean-Pierre Grünfeld; Laure-Hélène Noël; Jean-Michel Goujon; Bernadette Chadefaux-Vekemans; Corinne Antignac
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.